Home / Reports

Reports

Recommendations for developing generic medicines markets

The Sustaining Generic Medicines Markets in Europe report (April 2006), produced by the Research Centre for Pharmaceutical Care and Pharmaco-economics and authored by Professor Steven Simoens and Ms Sandra De Coster, offers a country-by-country analysis of generics markets in Europe and discusses factors both hindering and aiding the development of generics markets.

Strengths and weaknesses of developing generic medicines markets

The Sustaining Generic Medicines Markets in Europe report (April 2006), produced by the Research Centre for Pharmaceutical Care and Pharmaco-economics and authored by Professor Steven Simoens and Ms Sandra De Coster, offers a country-by-country analysis of generics markets in Europe and discusses factors both hindering and aiding the development of generics markets.

Strengths and weaknesses of developing mature medicines markets

The Sustaining Generic Medicines Markets in Europe report (April 2006), produced by the Research Centre for Pharmaceutical Care and Pharmaco-economics and authored by Professor Steven Simoens and Ms Sandra De Coster, offers a country-by-country analysis of generics markets in Europe and discusses factors both hindering and aiding the development of generics markets.

Recommendations for mature generic medicines markets

The Sustaining Generic Medicines Markets in Europe report (April 2006), produced by the Research Centre for Pharmaceutical Care and Pharmaco-economics and authored by Professor Steven Simoens and Ms Sandra De Coster, offers a country-by-country analysis of generics markets in Europe and discusses factors both hindering and aiding the development of generics markets.

Overview of the Sustaining Generic Medicines Markets in Europe

The Sustaining Generic Medicines Markets in Europe report (April 2006), produced by the Research Centre for Pharmaceutical Care and Pharmaco-economics and authored by Professor Steven Simoens and Ms Sandra De Coster, offers a country-by-country analysis of generics markets in Europe and discusses factors both hindering and aiding the development of generics markets.

Is China set to lose its low-cost appeal?

Over the last few years, with rising costs in Europe and the US, Western pharmaceutical companies have increasingly looked to outsource manufacturing to low-cost countries like China. However, inflation, rising costs and wage increases may change all this.

Opportunities in the COPD market

The increasing elderly population and increases in diagnosis and drug treatment will fuel a steady 4.6% annual growth in the chronic obstructive pulmonary disease (COPD) drug market, says a new report.

More drug recalls due to poor manufacturing

The quality of raw materials and contamination is under scrutiny by the FDA once again as Indian generics’ manufacturer Sun Pharmaceutical Industries Ltd is cited for manufacturing violations.

Opportunities for generic inhalation and nasal spray drugs

A new report from Espicom’s Senior Market Analyst, Mrs Karen Holmes, discusses emerging opportunities for inhalation and nasal spray drugs. It reviews currently available generic products and assesses the prospects for originator drugs losing patent protection over the next 10 years.

MSD-Chibret signs generics deal with French manufacturer

On 25 June 2010 Merck Sharp & Dohme-Chibret (MSD-Chibret) signed an agreement with subcontractor Fareva under an incentive set up by the strategic council of health industries (Csis) meeting, aimed at keeping pharmaceutical production in France.